Israel - Tiếng Anh - Ministry of Health

rafa laboratories ltd - ursodeoxycholic acid - film coated tablets - ursodeoxycholic acid 500 mg - ursodeoxycholic acid - ursodeoxycholic acid - for the symptomatic treatment of primary biliary cirrhosis (pbc), in patients without decompensated hepatic cirrhosis.

Canada - Tiếng Anh - Health Canada

merck canada inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg - biguanides

Canada - Tiếng Anh - Health Canada

apotex inc - desogestrel; ethinyl estradiol - tablet - 0.1500mg; 0.0300mg - desogestrel 0.1500mg; ethinyl estradiol 0.0300mg - contraceptives

Canada - Tiếng Anh - Health Canada

apotex inc - desogestrel; ethinyl estradiol - tablet - 0.1500mg; 0.0300mg - desogestrel 0.1500mg; ethinyl estradiol 0.0300mg - contraceptives

Canada - Tiếng Anh - Health Canada

merck canada inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg - biguanides

Canada - Tiếng Anh - Health Canada

takeda canada inc - alogliptin (alogliptin benzoate); metformin hydrochloride - tablet - 12.5mg; 500mg - alogliptin (alogliptin benzoate) 12.5mg; metformin hydrochloride 500mg - biguanides

Armenia - Tiếng Anh - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

quimica montpellier s.a. - metformin (metformin hydrochloride) - tablets film-coated - 500mg

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemfibrozil, quantity: 600 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; pregelatinised maize starch; calcium stearate; microcrystalline cellulose; polysorbate 80; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - gemfibrozil is indicated as an adjunct to diet and other therapeutic measures for the following: * severe hypertriglyceridaemia (types iv and v) in persons who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. * dyslipidaemia associated with diabetes. * reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. * because of potential toxicity such as malignancy, gall bladder disease, abdominal pain leading to appendicectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with the chemically and pharmacologically related drug clofibrate, the potential benefits of gemfibrozil in treating type iia patients with elevations of ldl choleserol only is not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above median hdl cholesterol values at baseline (greater than 1.2mmol/l), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. note: gemfibrozil is indicated when exercise, weight loss and specific dietary or other non-drug measures such as limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determinations of serum lipids should be obtained during treatment with gemfibrozil. the drug should be withdrawn or additionals therapy instituted if the lipid response is deemed inadequate after three months.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gemfibrozil, quantity: 600 mg - tablet, film coated - excipient ingredients: polysorbate 80; sodium lauryl sulfate; crospovidone; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; croscarmellose sodium; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - ausgem is indicated as an adjunct to diet and other therapeutic measures for the following conditions: -severe hypertiglyceridamia (types iv and v) in those who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. -dyslipidaemia associated with diabetes. -reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. beacause of potential toxicity such as malignancy, gallbladder disease, abnormal pain leading to appendectomy and other abdominal surgeries, an increased incidence in non-coronary mortality and the 29% increase in all-cause mortality seen with the chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating type iia patients with elevation of ldl-cholesterol only are not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above-median hdl-cholesterol values at baseline (>1.2mmol/l), both gemfibrozil and placebo subgroups had similar incidences of serious coronary events. note: ausgem is indicated when exercise, weight loss and specific dietary or other non-drug measures, for example, limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determinations of serum lipids should be obtained during treatment with ausgem. the drug should be withdrawn or additional therapy instituted if the lipid response is deemed inadequate after 3 months.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - gemfibrozil, quantity: 600 mg - tablet, film coated - excipient ingredients: crospovidone; polysorbate 80; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hyprolose; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - lipigem is indicated as an adjunct to diet and other therapeutic measures for: *severe hypertriglyceridaemia (type iv and v) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. *dyslipidaemia associated with diabetes. *reduction of risk of coronary heart disease in patients with type iia and iib hypercholesterolaemia. because of potential toxicity such as malignancy, gallbladder disease, abdominal pain leading to appendectomy and other abdominal surgeries, an increased incidence in noncoronary mortality, and the 29% increase in all-cause mortality seen with the chemically and pharmacologically related drug, clofibrate, the potential benefits of gemfibrozil in treating type iia patients with elevations of ldl-cholesterol only are not likely to outweigh the risks. in a subgroup analysis of patients in the helsinki heart study with above-median hdl-cholesterol values at baseline (greater than 1.2mmol/l), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups. note: lipigem is indicated when exercise, weight loss and specific dietary or other nondrug measures such as limiting alcohol intake have failed. other medical disorders such as hypothyroidism and diabetes should be controlled as much as possible. periodic determination of serum lipids should be obtained during treatment with lipigem. the drug should be withdrawn or additional therapy instituted if the lipid response is deemed inadequate after three months.